(CRSP) Crispr Therapeutics - Overview
Stock: Gene Editing, CAR-T, Hemoglobinopathies, Diabetes, Oncology
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 60.9% |
| Relative Tail Risk | -11.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.60 |
| Alpha | 2.96 |
| Character TTM | |
|---|---|
| Beta | 1.310 |
| Beta Downside | 0.775 |
| Drawdowns 3y | |
|---|---|
| Max DD | 64.91% |
| CAGR/Max DD | -0.02 |
Description: CRSP Crispr Therapeutics January 09, 2026
CRISPR Therapeutics AG (NASDAQ:CRSP) is a Swiss-based biotech that leverages its CRISPR/Cas9 platform to develop gene-edited medicines for high-unmet-need diseases, spanning hemoglobinopathies, oncology (CAR-T), in-vivo editing, and type-1 diabetes.
Its lead candidate, **CASGEVY**, is an ex-vivo edited hematopoietic stem-cell therapy designed to reactivate fetal hemoglobin, aiming for transfusion independence in beta-thalassemia and sickle-cell disease. Recent Phase 3 data (reported Q2 2024) showed >90 % of treated patients achieving transfusion-free status, a key efficacy milestone.
Beyond CASGEVY, the pipeline includes CAR-T programs such as **CTX112** (CD19) and **CTX131** (CD70), in-vivo editors **CTX310/CTX320** targeting ANGPTL3 and Lp(a) for cardiovascular risk reduction, and **CTX211**, an allogeneic, hypo-immune stem-cell product for type-1 diabetes. Strategic alliances with Vertex, Nkarta, and Capsida provide co-development funding and shared IP.
Financially, CRISPR reported cash and cash equivalents of **$1.2 billion** at the end of Q3 2024, giving it roughly 18 months of runway at current burn (~$70 million per quarter). The broader CRISPR therapeutics market is projected to grow at a **CAGR of ~20 %** through 2030, driven by accelerating regulatory approvals and expanding indications.
For a deeper dive into CRSP’s valuation metrics and risk-adjusted upside, the ValueRay platform offers a concise analyst toolkit.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -488.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA -5.03 > 1.0 |
| NWC/Revenue: 4808 % < 20% (prev 919.6%; Δ 3889 % < -1%) |
| CFO/TA -0.13 > 3% & CFO -302.5m > Net Income -488.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 16.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (91.3m) vs 12m ago 7.12% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 1.67% > 50% (prev 8.94%; Δ -7.26% > 0%) |
| Interest Coverage Ratio: -8.62 > 6 (EBITDA TTM -529.5m / Interest Expense TTM -63.6m) |
Altman Z'' -4.75
| A: 0.81 (Total Current Assets 1.93b - Total Current Liabilities 119.0m) / Total Assets 2.25b |
| B: -0.81 (Retained Earnings -1.82b / Total Assets 2.25b) |
| C: -0.24 (EBIT TTM -548.2m / Avg Total Assets 2.25b) |
| D: -5.49 (Book Value of Equity -1.81b / Total Liabilities 329.3m) |
| Altman-Z'' Score: -4.75 = D |
Beneish M -3.24
| DSRI: 0.67 (Receivables 25.0m/200.0m, Revenue 37.6m/201.6m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 2.23 (AQ_t 0.03 / AQ_t-1 0.01) |
| SGI: 0.19 (Revenue 37.6m / 201.6m) |
| TATA: -0.08 (NI -488.3m - CFO -302.5m) / TA 2.25b) |
| Beneish M-Score: -3.24 (Cap -4..+1) = AA |
What is the price of CRSP shares?
Over the past week, the price has changed by -3.14%, over one month by -7.69%, over three months by -8.94% and over the past year by +26.11%.
Is CRSP a buy, sell or hold?
- StrongBuy: 12
- Buy: 5
- Hold: 10
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the CRSP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 84.4 | 69.8% |
| Analysts Target Price | 84.4 | 69.8% |
| ValueRay Target Price | 51.1 | 2.7% |
CRSP Fundamental Data Overview February 03, 2026
P/S = 124.1933
P/B = 2.6536
P/EG = -0.2142
Revenue TTM = 37.6m USD
EBIT TTM = -548.2m USD
EBITDA TTM = -529.5m USD
Long Term Debt = 211.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 18.3m USD (from shortTermDebt, last quarter)
Debt = 211.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -75.5m USD (from netDebt column, last quarter)
Enterprise Value = 3.06b USD (4.76b + Debt 211.0m - CCE 1.92b)
Interest Coverage Ratio = -8.62 (Ebit TTM -548.2m / Interest Expense TTM -63.6m)
EV/FCF = -10.08x (Enterprise Value 3.06b / FCF TTM -303.1m)
FCF Yield = -9.92% (FCF TTM -303.1m / Enterprise Value 3.06b)
FCF Margin = -805.2% (FCF TTM -303.1m / Revenue TTM 37.6m)
Net Margin = -1297 % (Net Income TTM -488.3m / Revenue TTM 37.6m)
Gross Margin = unknown ((Revenue TTM 37.6m - Cost of Revenue TTM 171.5m) / Revenue TTM)
Tobins Q-Ratio = 1.36 (Enterprise Value 3.06b / Total Assets 2.25b)
Interest Expense / Debt = 8.43% (Interest Expense 17.8m / Debt 211.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -433.0m (EBIT -548.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 16.22 (Total Current Assets 1.93b / Total Current Liabilities 119.0m)
Debt / Equity = 0.11 (Debt 211.0m / totalStockholderEquity, last quarter 1.92b)
Debt / EBITDA = 0.14 (negative EBITDA) (Net Debt -75.5m / EBITDA -529.5m)
Debt / FCF = 0.25 (negative FCF - burning cash) (Net Debt -75.5m / FCF TTM -303.1m)
Total Stockholder Equity = 1.85b (last 4 quarters mean from totalStockholderEquity)
RoA = -21.70% (Net Income -488.3m / Total Assets 2.25b)
RoE = -26.44% (Net Income TTM -488.3m / Total Stockholder Equity 1.85b)
RoCE = -26.63% (EBIT -548.2m / Capital Employed (Equity 1.85b + L.T.Debt 211.0m))
RoIC = -23.44% (negative operating profit) (NOPAT -433.0m / Invested Capital 1.85b)
WACC = 10.57% (E(4.76b)/V(4.97b) * Re(10.74%) + D(211.0m)/V(4.97b) * Rd(8.43%) * (1-Tc(0.21)))
Discount Rate = 10.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.96%
Fair Price DCF = unknown (Cash Flow -303.1m)
EPS Correlation: 37.77 | EPS CAGR: 93.08% | SUE: 2.46 | # QB: 1
Revenue Correlation: -3.81 | Revenue CAGR: -51.00% | SUE: -0.27 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.11 | Chg30d=-0.015 | Revisions Net=+1 | Analysts=6
EPS next Year (2026-12-31): EPS=-4.43 | Chg30d=+0.034 | Revisions Net=+0 | Growth EPS=+28.2% | Growth Revenue=+1911.8%